Upregulation of Human Endogenous Retroviruses in Bronchoalveolar Lavage Fluid of COVID-19 Patients - Kitsou, Konstantina; Kotanidou, Anastasia; Paraskevis, Dimitrios; Karamitros, Timokratis; Katzourakis, Aris; Tedder, Richard; Hurst, Tara; Sapounas, Spyros; Kotsinas, Athanassios; Gorgoulis, Vassilis; Spoulou, Vana; Tsiodras, Sotirios; et al. (medRxiv, 2020)
Background Severe COVID-19 pneumonia has been associated with the development of intense inflammatory responses during the course of infections with SARS-CoV-2. Given that Human Endogenous Retroviruses (HERVs) are known to be activated during and participate in inflammatory processes, we examined whether HERV dysregulation signatures are present in COVID-19 patients.Results By comparing transcriptomes of Peripheral Blood Monocytes (PBMCs) and Bronchoalveolar Lavage Fluid (BALF) from patients and normal controls we have shown that HERVs are intensely dysregulated in BALF, but not in PBMCs. In particular, upregulation in the expression of multiple HERV families was detected in BALF samples of COVID-19 patients, with HERV-W being the most highly upregulated family among the families analysed. In addition, we compared the expression of HERVs in Human Bronchial Epithelial Cells (HBECs) without and after senescence induction in an oncogene-induced senescence model, in order to quantitatively measure changes in the expression of HERVs in bronchial cells during the processes of cellular senescence.Conclusions This apparent difference of HERV dysregulation between PBMCs and BALF warrants further studies in involvement of HERVs in inflammatory pathogenetic mechanisms as well as exploration of HERVs as potential biomarkers for disease progression. Furthermore, the increase in the expression of HERVs in senescent HBECs in comparison to non-induced HBECs provides a potential link for increased COVID-19 severity and mortality in aged populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEmblematic action to handle SARS-CoV-2 infection: Epidemiological study in Greece via extensive testing for viral and antibody detection, sequencing of the virome and genetic analysis of the carriers (GSRT No 2020ΣE01300001).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets of the PBMCs from COVID-19 patients and healthy volunteers, as well as the data of BALF from COVID-19 patients analysed during the current study are available in National Genomics Data Center-Genome Sequence Archive (NGDC-GSA), in BIG Data Center (https://bigd.big.ac.cn/), Beijing Institute of Genomics (BIG), Chinese Academy of Sciences with accession numbers CRR119890, CRR119891, CRR119892, CRR119893, CRR119894, CRR119895, CRR119896, CRR119897, CRR125445 and CRR125446.The datasets of BALF from healthy controls analysed in the present work are available in NCBI-Sequence read Archive (SRA), under accession numbers: SRR10571724, SRR10571730, SRR10571732.The datasets of the induced and non-induced HBECs analysed in the present work are available in NCBI-Sequence read Archive (SRA), under accession numbers: SRR6261633, SRR6261634, SRR6261635, SRR6261636, SRR6261637, SRR6261638, SRR6261639, SRR6261640, SRR6261641, SRR6261642, SRR6261643, SRR6261644, SRR6261645, SRR626163346, SRR6261647, SRR6261648, SRR6261649, SRR6261650, SRR6261651, SRR6261652, SRR6261653, SRR6261654, SRR6261655, SRR6261656.https://bigd.big.ac.cn/gsa/browse/CRA002390https://www.ncbi.nlm.nih.gov/sra/?term=srr10571724https://www.ncbi.nlm.nih.gov/sra/?term=srr10571730https://www.ncbi.nlm.nih.gov/sra/?term=srr10571732https://www.ncbi.nlm.nih.gov/sra?term=SRX3367915https://www.ncbi.nlm.nih.gov/sra?term=SRX3367916https://www.ncbi.nlm.nih.gov/sra?term=SRX3367917https://www.ncbi.nlm.nih.gov/sra?term=SRX3367918https://www.ncbi.nlm.nih.gov/sra?term=SRX3367919https://www.ncbi.nlm.nih.gov/sra?term=SRX3367920